分子影像引导HER2阳性肿瘤诊疗新进展
DOI: 10.3971/j.issn.1000-8578.2019.18.0796
Keywords: A Scientometric Analysis,A Case Report of Four Primary Malignant Tumors,Research Progress of Intestinal Microbiota and Immune Checkpoint Inhibitors,Advances in Role of Cyclooxygenase 2 in Development and Progression of Cancer,Dedifferentiated Liposarcoma of Testis: A Case Report and Literature Review,A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer,Diffusion-weighted Magnetic Resonance Imaging Evaluates Salivary Gland Function Damage in Nasopharyngeal Carcinoma Patients Treated with Intensity-modulated Radiation Therapy,Research Advances on Effect of Adipose-derived Stem Cells on Biological Characteristics of Breast Cancer,Advances of 125I Radioactive Particle Chain Intracavitary Brachytherapy,Expression of Infiltrating NK Cell Surface Receptors in Peripheral Blood and Cancer Tissues of Patients with Esophageal Squamous Cell Carcinoma,Risk Factors of Pathological Upstaging for Patients with Clinical T2N0M0 Esophageal Squamous Cell Carcinoma,Progress of Stimulation Response Strategy Based on Nanomaterials in Tumor Therapy
Abstract:
摘要 HER2既是靶向治疗的预测因子，又是明确的疗效预后因子，HER2阳性肿瘤恶性度高、侵袭性强，转移和复发早、患者预后差。因此，对肿瘤患者HER2状态的准确评估是提高疗效的关键，明确在体HER2状态至关重要。然而HER2状态在恶性肿瘤的靶向治疗中表现出高度异质性，IHC/FISH等经典方法均无法实现在体、实时、动态监测HER2表达状态，并且无法精确定位，难以达到HER2高表达肿瘤早期诊疗和精准治疗的要求。随着分子影像学的飞速发展，快速、精准、无创、有效评价肿瘤免疫治疗药物效果的分子探针出现，将能够成为解决肿瘤异质性问题的关键。本综述以目前已有的HER2分子探针为起点，对分子影像引导肿瘤靶向治疗发展趋势进行分析
Full-Text
